Oragenics Inc.

Oragenics Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Oragenics Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Oragenics Inc..
Log in to see more information.
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotic...
OGEN Fundamental Data by TradingView

News

Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Closing of Public Offering

Globe Newswire SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...\n more…

Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. Announces Pricing of Public Offering

Globe Newswire SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...\n more…

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Globe Newswire Falls and car accidents lead incidence of concussions in emergency departments Spray-dried drug formulation allows for easy delivery to patients No pharmaceutical treatment is available for...\n more…

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Globe Newswire SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...\n more…

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Globe Newswire ONP-002 stability eliminates need for cumbersome cold storage No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc...\n more…

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Globe Newswire ONP-002 showed no cancer-causing DNA damage Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on...\n more…